Literature DB >> 1886440

The treatment of small acoustic tumors: now or later?

C Shelton1, W E Hitselberger.   

Abstract

Prior to the advent of microneurosurgery, the operative mortality for acoustic tumor removal was high and management often consisted of observation until sufficient symptoms warranted removal. The treatment of these tumors has evolved, and recent introduction of gadolinium-enhanced magnetic resonance imaging (MRI) allows the diagnosis of very small intracanalicular acoustic tumors before hearing has been significantly affected. For such tumors, some surgeons advocate the premicrosurgical philosophy of observation rather than removal. Our results of small acoustic tumor removal with attempt at hearing preservation were reviewed. From 1961 to June 1989, 39 acoustic tumors 0.5 cm or less were removed by the middle fossa approach. Measurable hearing was preserved in 67%, and facial function 1 year postoperatively was normal or nearly normal in 97%. There was no other permanent operative morbidity. Given our results, early surgical removal of small acoustic tumors is advocated.

Entities:  

Mesh:

Year:  1991        PMID: 1886440     DOI: 10.1288/00005537-199109000-00002

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  4 in total

1.  Malignant vestibular schwannoma.

Authors:  B Gruber; L Petchenik; M Williams; C Thomas; M G Luken
Journal:  Skull Base Surg       Date:  1994

2.  Decision making in acoustic neuroma management: the only hearing ear.

Authors:  M B Naguib; E Saleh; M Aristegui; A Mazzoni; M Sanna
Journal:  Skull Base Surg       Date:  1994

3.  Surgical management of vestibular schwannoma in elderly patients.

Authors:  Amjad Nuseir; Giuliano Sequino; Giuseppe De Donato; Abdelkader Taibah; Mario Sanna
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-03-24       Impact factor: 2.503

4.  Management of acoustic neuroma in the only hearing ear.

Authors:  Maged B Naguib; Yasar Cokkeser; Mario Sanna
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-04-30       Impact factor: 2.503

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.